Citation Impact
Citing Papers
Mammalian Target of Rapamycin Inhibition Promotes Response to Epidermal Growth Factor Receptor Kinase Inhibitors in PTEN-Deficient and PTEN-Intact Glioblastoma Cells
2006
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist
2004 StandoutNobel
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule
2004
The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
2002
Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase
2004
ErbB Receptors: Directing Key Signaling Networks Throughout Life
2004
Disruption of Parallel and Converging Signaling Pathways Contributes to the Synergistic Antitumor Effects of Simultaneous mTOR and EGFR Inhibition in GBM Cells
2005
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
2003
Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib
2008
Engineered receptors for soluble cellular communication and disease sensing
2024 StandoutNatureNobel
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
2008 StandoutNature
The promise and challenge of therapeutic genome editing
2020 StandoutNatureNobel
Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
1997
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007 Standout
ErbB-targeted therapeutic approaches in human cancer
2003
Memo mediates ErbB2-driven cell motility
2004
Targeting HIF-1 for cancer therapy
2003 StandoutNobel
Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents
2003
Phosphate Recognition in Structural Biology
2006
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Mechanism-based design of a protein kinase inhibitor.
2001
Phosfinder: a web server for the identification of phosphate-binding sites on protein structures
2011
The Drosophila Circadian Network Is a Seasonal Timer
2007 StandoutNobel
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
2007 StandoutNature
Malignant astrocytic glioma: genetics, biology, and paths to treatment
2007 Standout
Multiplexed droplet single-cell RNA-sequencing using natural genetic variation
2017
Asymmetric Synthesis of Selectively Protected Amino Sugars and Derivatives by a Direct Organocatalytic Mannich Reaction
2005
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
1996 Standout
Cooperation between Fibroblast Growth Factor Receptor-4 and ErbB2 in Regulation of Cyclin D1 Translation
2004
Brain tumors: molecular biology and targeted therapies
2006
Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor
2002
Heat Sensitization in Skin and Muscle Nociceptors Expressing Distinct Combinations of TRPV1 and TRPV2 Protein
2007
Molecularly targeted therapy for malignant glioma
2007
Targeting cancer with small molecule kinase inhibitors
2008 Standout
Regulation of Hypoxia-Inducible Factor-1α, Vascular Endothelial Growth Factor, and Angiogenesis by an Insulin-Like Growth Factor-I Receptor Autocrine Loop in Human Pancreatic Cancer
2003 StandoutNobel
Targeting the function of the HER2 oncogene in human cancer therapeutics
2007
CRISPR/Cas9-Based Engineering of the Epigenome
2017
Targeted Molecular Therapy of GBM
2003
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
2012 StandoutNobel
Selectivity of 4,5,6,7‐tetrabromobenzotriazole, an ATP site‐directed inhibitor of protein kinase CK2 (‘casein kinase‐2’)
2001
Bridge helix arginines play a critical role in Cas9 sensitivity to mismatches
2020 StandoutNobel
Cellular and Molecular Mechanisms of Pain
2009 StandoutNobel
Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies
2020
A Role for the Segment Polarity Gene shaggy/GSK-3 in the Drosophila Circadian Clock
2001 StandoutNobel
Interactions with Aromatic Rings in Chemical and Biological Recognition
2003 Standout
The next generation of CRISPR–Cas technologies and applications
2019
Inositol trisphosphate and calcium signalling
1993 StandoutNature
Blockade of Epidermal Growth Factor Receptor Signaling on Tumor Cells and Tumor-Associated Endothelial Cells for Therapy of Human Carcinomas
2002
Signalling from adenosine receptors to mitogen-activated protein kinases
2003
Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with In Vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785)
1999
Optical Pooled Screens in Human Cells
2019
ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression
2001
Impact of EGFR point mutations on the sensitivity to gefitinib: Insights from comparative structural analyses and molecular dynamics simulations
2006
Treatment of Philadelphia‐chromosome‐positive human leukemia in scid mouse model with herbimycin A, bcr‐abl tyrosine kinase activity inhibitor
1995 StandoutNobel
Topoisomerase I inhibitors: camptothecins and beyond
2006 Standout
BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer
2006
Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters
2005
Organoid single-cell genomic atlas uncovers human-specific features of brain development
2019 StandoutNatureNobel
Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors
2001
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 Standout
Phosphate binding sites identification in protein structures
2010
Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity
2007
Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells
2003
Simple yet functional phosphate-loop proteins
2018 StandoutNobel
The Direct Catalytic Asymmetric Three-Component Mannich Reaction
2000 StandoutNobel
The kinase Grk2 regulates Nedd4/Nedd4-2-dependent control of epithelial Na + channels
2004 StandoutNobel
Roles of the Two Drosophila CRYPTOCHROME Structural Domains in Circadian Photoreception
2004 StandoutScienceNobel
Tumour stem cells and drug resistance
2005 Standout
Direct catalytic asymmetric Mannich-type reaction of unmodified ketones utilizing the cooperation of an AlLibis(binaphthoxide) complex and La(OTf)3·nH2O
1999
Design and Synthesis of 5-Aryl-pyridone-carboxamides as Inhibitors of Anaplastic Lymphoma Kinase
2006
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
2000
Ramshackle (Brwd3) promotes light-induced ubiquitylation of Drosophila Cryptochrome by DDB1-CUL4-ROC1 E3 ligase complex
2013 StandoutNobel
CRISPRi and CRISPRa Screens in Mammalian Cells for Precision Biology and Medicine
2017
Decrease in topoisomerase I is responsible for activation-induced cytidine deaminase (AID)-dependent somatic hypermutation
2011 StandoutNobel
Multidrug Transporter ABCG2 Prevents Tumor Cell Death Induced by the Epidermal Growth Factor Receptor Inhibitor Iressa (ZD1839, Gefitinib)
2005
Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non–Small-Cell Lung Cancer
2005
Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation.
2001
A Library Approach to the Generation of Bisubstrate Analogue Sulfotransferase Inhibitors
2001 StandoutNobel
Synthesis of a Bisubstrate Analogue Targeting Estrogen Sulfotransferase
2002 StandoutNobel
Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme
2005
Development and Applications of Disulfonimides in Enantioselective Organocatalysis
2015 StandoutNobel
Association with HSP90 Inhibits Cbl-Mediated Down-regulation of Mutant Epidermal Growth Factor Receptors
2006
AID-induced decrease in topoisomerase 1 induces DNA structural alteration and DNA cleavage for class switch recombination
2009 StandoutNobel
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition
2002
Reaction mechanism of Drosophila cryptochrome
2010 StandoutNobel
Gefitinib Reverses Chemotherapy Resistance in Gefitinib-Insensitive Multidrug Resistant Cancer Cells Expressing ATP-Binding Cassette Family Protein
2005
Fluorine in Pharmaceuticals: Looking Beyond Intuition
2007 StandoutScience
Tyrosine Kinase Inhibitors. 11. Soluble Analogues of Pyrrolo- and Pyrazoloquinazolines as Epidermal Growth Factor Receptor Inhibitors: Synthesis, Biological Evaluation, and Modeling of the Mode of Binding
1997
Spin—spin coupling and the conformational states of peptide systems
1976
Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy
2004
Cancer Genome Landscapes
2013 StandoutScience
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
Gefitinib reverses breast cancer resistance protein–mediated drug resistance
2004
Design and Structure−Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors
1999
Tyrosine Kinase Inhibition: An Approach to Drug Development
1995 Science
Novel Combinations Based on Epidermal Growth Factor Receptor Inhibition
2006
Activation of MAP kinases by calcium-dependent and calcium-independent pathways. Stimulation by thapsigargin and epidermal growth factor.
1992
Catalytic Enantioselective Allylation of Carbonyl Compounds and Imines
2011
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
CRISPR-Cas guides the future of genetic engineering
2018 StandoutScienceNobel
Compact Biocompatible Quantum Dots Functionalized for Cellular Imaging
2008 StandoutNobel
Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas
2006
NMR scalar couplings across Watson–Crick base pair hydrogen bonds in DNA observed by transverse relaxation-optimized spectroscopy
1998 StandoutNobel
Asymmetric Enamine Catalysis
2007 StandoutNobel
Top-down design of protein architectures with reinforcement learning
2023 StandoutScienceNobel
Attenuated T 2 relaxation by mutual cancellation of dipole–dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution
1997 StandoutNobel
Simultaneous Blockade of Platelet-Derived Growth Factor-Receptor and Epidermal Growth Factor-Receptor Signaling and Systemic Administration of Paclitaxel as Therapy for Human Prostate Cancer Metastasis in Bone of Nude Mice
2004
Production of ‘hybrid’ antibiotics by genetic engineering
1985 StandoutNatureNobel
JNK1 controls mast cell degranulation and IL-1β production in inflammatory arthritis
2010 StandoutNobel
The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease
2006 StandoutScience
A Role for the Proteasome in the Light Response of the Timeless Clock Protein
1999 Science
X-ray Crystal Structure of a Bisubstrate Inhibitor Bound to the Enzyme Catechol-O-methyltransferase: A Dramatic Effect of Inhibitor Preorganization on Binding Affinity
2001
Works of Peter Traxler being referenced
Thiazolidine-diones. Biochemical and biological activity of a novel class of tyrosine protein kinase inhibitors.
1990
Sulfonylbenzoyl-nitrostyrenes: Potential bisubstrate type inhibitors of the EGF-receptor tyrosine protein kinase
1991
Tyrosine kinases as targets in cancer therapy – successes and failures
2003
Strategies toward the Design of Novel and Selective Protein Tyrosine Kinase Inhibitors
1999
Tyrosine kinase inhibitors: From rational design to clinical trials
2001
Modelling study of protein kinase inhibitors: Binding mode of staurosporine and origin of the selectivity of CGP 52411
1995
Pooled CRISPR screening with single-cell transcriptome readout
2017
[(Alkylamino)methyl]acrylophenones: Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor Protein Tyrosine Kinase
1995
4,5-bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity.
1995
Tyrosine kinase targets in drug discovery
2003
Isolation and structural elucidation of 3,6-dioxo-hexahydro-pyrrolo [1,2-a]-pyrazine from the echinodermLuidia clathrata
1973
ATP site-directed competitive and irreversible inhibitors of protein kinases
2000
Papulacandins, a new family of antibiotics with antifungal activity. I. Fermentation, isolation, chemical and biological characterization of papulacandins A, B, C, D and E.
1977
Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.
2000
AEE788
2004
Use of a Pharmacophore Model for the Design of EGFR Tyrosine Kinase Inhibitors: Isoflavones and 3-Phenyl-4(1H)-quinolones
1999
Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
1997
Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 in Vitro
2004
Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma.
2001
4-(Phenylamino)pyrrolopyrimidines: Potent and Selective, ATP Site Directed Inhibitors of the EGF-Receptor Protein Tyrosine Kinase
1996
Use of a Pharmacophore Model for the Design of EGF-R Tyrosine Kinase Inhibitors: 4-(Phenylamino)pyrazolo[3,4-d]pyrimidines
1997
Synthesis of Modified Tripeptides and Tetrapeptides as potential bisubstrate inhibitors of the epidermal growth factor receptor protein tyrosine kinase
1997
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition
2005
3-Hydroxyrifamycin S and further novel ansamycins from a recombinant strain R-21 of Nocardia mediterranei.
1981
Zur Struktur von Papulacandin B, einem neuen antifungischen Antibiotikum. Vorläufige Mitteilung
1977
Papulacandins, a new family of antibiotics with antifungal activity. Structures of papulacandins A, B, C and D.
1980